193 related articles for article (PubMed ID: 5211352)
1. The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters.
Withey RJ; Feng H; Cook D; Van Petten GR; Lettau HF
J Clin Pharmacol New Drugs; 1971; 11(3):187-96. PubMed ID: 5211352
[No Abstract] [Full Text] [Related]
2. The physiologic availability of solid dosage forms of phenylbutazone. I. In vivo physiologic availability and pharmacologic considerations.
Van Petten GR; Feng H; Withey RJ; Lettau HF
J Clin Pharmacol New Drugs; 1971; 11(3):177-86. PubMed ID: 5211351
[No Abstract] [Full Text] [Related]
3. [Biological availability and solubility of phenylbutazone].
Krówczyński L; Jachowicz R; Wajdowicz A
Folia Med Cracov; 1979; 21(1):141-7. PubMed ID: 396188
[No Abstract] [Full Text] [Related]
4. Biopharmaceutical assessment of phenylbutazone and indomethacin preparations.
Turakka H; Airaksinen MM
Ann Clin Res; 1974; 6(0):suppl 11:34-43. PubMed ID: 4855463
[No Abstract] [Full Text] [Related]
5. Evaluation of dosage forms. IV. Studies on commercial phenylbutazone tablet dosage forms.
Razdan B; Paradkar AR
Drug Dev Ind Pharm; 1998 Jul; 24(7):599-604. PubMed ID: 9876503
[TBL] [Abstract][Full Text] [Related]
6. The objective and timing of drug disposition studies, appendix IV. Phenylbutazone formulations: in vitro dissolution and in vivo performance.
Leeson LJ; Shinal EC; Lukas G; Zak SB; Weiner M
Drug Metab Rev; 1975; 4(2):277-84. PubMed ID: 1222684
[TBL] [Abstract][Full Text] [Related]
7. The varying dissolution rates of phenylbutazone tablets.
Thomas WH; McCarthy WB
N Z Med J; 1970 Oct; 72(461):250-3. PubMed ID: 5275017
[No Abstract] [Full Text] [Related]
8. The physiologic availability of phenylbutazone tablets marketed in India.
Manek SP; Tipnis HP; Kulkarni RD
Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):163-7. PubMed ID: 7263103
[TBL] [Abstract][Full Text] [Related]
9. A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form.
Souliman S; Blanquet S; Beyssac E; Cardot JM
Eur J Pharm Sci; 2006 Jan; 27(1):72-9. PubMed ID: 16169713
[TBL] [Abstract][Full Text] [Related]
10. Phenylbutazone.
Leeson LJ
Pharmacology; 1972; 8(1):154-63. PubMed ID: 4644645
[No Abstract] [Full Text] [Related]
11. Determination of physiologic availability of commercial phenylbutazone preparations.
Chiou WL
J Clin Pharmacol New Drugs; 1972 Jul; 12(7):296-300. PubMed ID: 4483535
[No Abstract] [Full Text] [Related]
12. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. Part 5: In vitro/in vivo correlation for chlorpromazine hydrochloride tablets.
Ammar HO; Khalil RM; Omar SM
Pharmazie; 1993 Dec; 48(12):932-5. PubMed ID: 8115438
[TBL] [Abstract][Full Text] [Related]
13. [Automatic system for evaluation of the velocity of dissolution rate of solid dosage forms].
Zecchi V; Cini M; Rodriguez L; Magnani M
Boll Chim Farm; 1979 Mar; 118(3):168-75. PubMed ID: 475908
[No Abstract] [Full Text] [Related]
14. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
15. Non-equivalence of digoxin tablets.
Reissell P; Manninen V; Ojala K; Karjalainen J
Ann Clin Res; 1974; 6(0):suppl 11:4-8. PubMed ID: 4853359
[No Abstract] [Full Text] [Related]
16. The biopharmaceutical properties of solid dosage forms. I. An evaluation of 23 brands of phenylbutazone tablets.
Searl RO; Pernarowski M
Can Med Assoc J; 1967 Jun; 96(23):1513-20. PubMed ID: 6026336
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
18. Correlation between the rate of dissolution and absorption of opipramol from solid oral forms.
Kanarkowski R; Wichliński LM
Mater Med Pol; 1985; 17(2):85-7. PubMed ID: 4079473
[No Abstract] [Full Text] [Related]
19. [Differentiation of the degree of bioavailability of peroral drug forms of tetracycline hydrochloride in experiments on laboratory animals].
Zak AF; Ermolova OB
Antibiotiki; 1976 Feb; 21(2):151-5. PubMed ID: 1275466
[TBL] [Abstract][Full Text] [Related]
20. Fast-dissolving microparticles fail to show improved oral bioavailability.
Wong SM; Kellaway IW; Murdan S
J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
